PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project


  • Blons H.
  • Oudart J.-B.
  • Merlio J.-P.
  • Debieuvre D.
  • de Fraipont F.
  • Audigier-Valette C.
  • Escande F.
  • Hominal S.
  • Bringuier P-P
  • Fraboulet-Moreau S.
  • Ouafik L.
  • Moro-Sibilot D.
  • Lemoine A.
  • Langlais A
  • Missy P.
  • Morin F.
  • Souquet P.-J.
  • Barlesi F.
  • Cadranel J.
  • Beau-Faller M
  • Bringuier P.‐p.
  • Beau‐faller M.


  • EGFR mutations
  • Molecular profiles
  • Next-generation sequencing
  • Non-small cell lung cancer
  • Prognosis


Tumor mutation screening is standard of care for patients with stage IV NSCLC. Since a couple of years, widespread NGS approaches used in routine diagnostics to detect driver mutations such as EGFR, KRAS, BRAF or MET allows the identification of other alterations that could modulated the intensity or duration of response to targeted therapies. The prevalence of co-occurring alterations that could affect response or prognosis as not been largely analyzed in clinical settings and large cohorts of patients. Thanks to the IFCT program "Biomarkers France", a collection of samples and data at a nation-wide level was available to test the impact of co-mutations on first line EGFR TKI in patients with EGFR mutated cancers.

more information